<DOC>
	<DOC>NCT00108797</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.</brief_summary>
	<brief_title>Trial of NovoSeven® in Haemophilia - Joint Bleeds</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>